Clinical Trials

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

33 enrolled

Lymphoid

Lymphoma, Follicular

NCT07413354 2026-02-17

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Carcinoma, Hepatocellular

NCT07131319 2026-02-02

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07370337 2026-01-27

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

Phase EARLY_PHASE1 Recruiting

50 enrolled

Squamous Cell Carcinoma of External Auditory Canal

NCT07341360 2026-01-14

Pseudovax

10 enrolled

Pseudomyxoma Peritonei

NCT06312982 2026-01-13

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

Phase 2/3 Recruiting

375 enrolled

Locally Advanced Rectal Carcinoma

NCT07330037 2026-01-09

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

41 enrolled

NSCLC

NCT07317609 2026-01-05

Endosurgery-02

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06722183 2025-12-24

FUTURE

33 enrolled

Colorectal Neoplasms

NCT07296705 2025-12-22

HARBOR

25 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07059299 2025-12-19

NeoTISLEGA

18 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06349837 2025-12-17

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

24 enrolled

Solid Tumor

NCT05977673 2025-12-08

FIL_Tisle-HL

28 enrolled

Lymphoid

Hodgkin Disease, Lymphoma

NCT07264647 2025-12-04

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07243691 2025-11-24

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

Phase NA Recruiting

33 enrolled

Carcinoma, Hepatocellular

NCT07233252 2025-11-18

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

35 enrolled

Genitourinary

Renal Pelvic Carcinoma

NCT06529523 2025-10-07

Tislelizumab in People With Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT06838208 2025-09-24

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

56 enrolled

Small Cell Lung Carcinoma

NCT06893380 2025-09-15

GENTIS

Recruiting

61 enrolled

Biliary Tract Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

130 enrolled

Rectal Neoplasms

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

29 enrolled

Head and Neck Neoplasms

NCT07086456 2025-07-25

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

183 enrolled

Advanced Solid Tumor

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07047586 2025-07-03

LEAF-01

146 enrolled

Carcinoma, Hepatocellular

NCT07010120 2025-06-13

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

29 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06446726 2025-06-06

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

NCT06969612 2025-06-06

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

21 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06157996 2025-05-30

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

92 enrolled

Stomach Neoplasms

NCT06598527 2025-05-29

SACTION2401

Phase 3 Recruiting

360 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06659042 2025-05-18

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06848465 2025-05-11

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

9 enrolled

Colorectal Neoplasms

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

160 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06939127 2025-04-22

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06673693 2025-04-16

NEOSTART

24 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05984602 2025-04-15

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

10 enrolled

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

10 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT06541639 2025-03-18

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

78 enrolled

Advanced or Recurrent Solid Tumors

NCT06881537 2025-03-18

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

15 enrolled

Locally Recurrent Colorectal Cancer

NCT06258811 2025-03-13

Neoadjuvant Immunochemotherapy for LAOSCC

Phase 3 Recruiting

134 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04954781 2025-02-27

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

25 enrolled

Cholangiocarcinoma

NCT06032845 2025-02-27

CASTLE-11

25 enrolled

Solid Tumor, Adult

NCT06829355 2025-02-17

THYMI

52 enrolled

MCRC

NCT05920863 2025-02-11

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

35 enrolled